Aurobindo Pharma USA finalizes acquisition of Lannett Company following antitrust approval

Aurobindo Pharma USA Inc. has concluded its acquisition of U.S.-based generic drugmaker Lannett Company, Inc. after securing antitrust clearance from the Federal Trade Commission, establishing the entity as a wholly owned subsidiary.

According to official corporate disclosures, Aurobindo Pharma USA Inc. has completed its acquisition of Lannett Company, Inc. from Lannett Seller Holdco, Inc. The transaction was finalized on June 29, 2026, following formal regulatory clearance from the U.S. Federal Trade Commission on June 18, 2026. Under the new corporate structure, the acquired business has transitioned into a wholly owned subsidiary operating under the name Lannett Company LLC. Aurobindo Pharma USA Inc. is the North American operational arm of India-based multinational pharmaceutical manufacturer Aurobindo Pharma Limited, which specializes in large-scale generic medicines, active pharmaceutical ingredients, and specialized formulations.

The successful execution of this transaction marks an aggressive step by the parent group to expand its manufacturing footprint and market share within the highly competitive United States healthcare ecosystem. This consolidation directly impacts North American pharmaceutical supply chains, hospital procurement consortiums, generic drug distribution channels, and localized healthcare labor markets.

For industry executives and institutional investors, the swift immediate integration phase underscores a strategic focus on preserving operational continuity and product availability across key therapeutics. By folding Lannett's legacy domestic manufacturing capacity and established commercial networks into its massive global supply chain, Aurobindo mitigates regulatory compliance pressures and positions itself to extract deeper cost efficiencies, directly influencing price dynamics and competitive positioning in the Western generic medicines sector.